Key result
The Thro-HL risk model stratified classical Hodgkin lymphoma patients into low, intermediate, and high thrombotic risk groups with event rates of 2.7%, 16%, and 25%, respectively (P < 0.001).
Why the study?
Currently, there is no univocal indication to perform thromboprophylaxis in classical Hodgkin lymphoma.
Does the Thro-HL score better predict thrombotic risk compared to Khorana and ThroLy scores in patients with classical Hodgkin lymphoma?
Population
470 consecutive cHL patients without thromboprophylaxis treated from 2014 to 2022 outside clinical trials
Comparison
Validation of Khorana and ThroLy scores and assessment of risk factors for thrombotic events
Design
Multicenter retrospective cohort study
Authors
Loading...
Enables thrombotic risk stratification in classical Hodgkin lymphoma; leaves open clinical utility pending prospective validation.
Cohort (n=470)
Yes
Does the Thro-HL score better predict thrombotic risk compared to Khorana and ThroLy scores in patients with classical Hodgkin lymphoma?
Absolute Event Rate: 25% vs 2.7%
p-value: p=< 0.001
The newly developed Thro-HL score effectively stratifies thrombotic risk in patients with classical Hodgkin lymphoma, whereas existing Khorana and ThroLy scores did not significantly predict risk in this cohort.
Assanto et al. (2025) conducted a cohort in Classical Hodgkin lymphoma (n=470). High-risk Thro-HL score (>3) vs. Low-risk Thro-HL score (0-1) was evaluated on Thrombotic event (p=< 0.001). The Thro-HL risk model stratified classical Hodgkin lymphoma patients into low, intermediate, and high thrombotic risk groups with event rates of 2.7%, 16%, and 25%, respectively (P < 0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: